NCT01497665

GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)

A Phase II, Multi-center, Open-label Study Evaluating the Efficacy and Safety of GRN1005 in Non-Small Cell Lung Cancer Patients With Brain Metastases

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Angiochem Inc · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the efficacy, safety, and tolerability of GRN1005 in patients with brain metastases from non-small cell lung cancer (NSCLC).

Conditions

• Non-small Cell Lung Cancer (NSCLC) With Brain Metastases

Interventions

Type	Name	Description
DRUG	GRN1005	650 mg/m2 IV every 3 weeks

Timeline

• Start date: 2011-11-01
• Primary completion: 2013-01-01
• Completion: 2013-02-01
• First posted: 2011-12-22
• Last updated: 2019-01-22
• Results posted: 2015-12-14

Locations

10 sites across 2 countries: United States, Canada